Gilead Sciences Inc. (GILD)
Health Care5 articles
Price chart
Gilead Sciences Inc. (GILD) overview
Gilead Sciences is a biopharmaceutical company known for its HIV and antiviral therapies. It is a member of the S&P 500 and is classified in the Health Care sector — pharmaceutical, biotech, device and managed-care companies.
Gilead Sciences Inc. trades on the NasdaqGS under the ticker symbol GILD. As of the most recent market data, the stock was priced around $134.28, down 1.48% on the session, giving Gilead Sciences Inc. a market capitalization of roughly $166.72B.
Over the past 52 weeks, GILD has traded between $107.75 and $157.29. Shares are valued at a trailing price-to-earnings (P/E) ratio of about 18.5, a common gauge of how richly the market prices the company's earnings. Gilead Sciences Inc. also pays a dividend, currently yielding around 2.41%.
Key statistics
Informational only, not financial advice. Content is AI-generated and may contain errors. How this works.
Why investors watch GILD
As one of the larger companies in the Health Care sector, Gilead Sciences Inc. is closely followed by investors and often moves with broader trends across pharmaceutical, biotech, device and managed-care companies. Traders watch GILD for earnings reports, analyst rating changes, and headlines that can shift sentiment — each of which is summarized on this page as it breaks.
Because the S&P 500 is weighted by market value, Gilead Sciences Inc.'s size means its share-price moves can also nudge the index as a whole, making GILD a stock that even index investors pay attention to.
Market Mood
Latest GILD news
Gilead Sciences (GILD) Stock Rating Reiterated After HIV Drug Approval
Cantor Fitzgerald has reiterated its rating on Gilead Sciences (GILD) following the approval of a new HIV drug. The approval is significant as it supports Gilead's position in the HIV treatment market. Market analysts are closely watching the impact of this approval on Gilead's stock performance and overall revenue growth. Investors should consider this reaffirmed rating when evaluating their positions in GILD, given the potential for increased sales.
Read More: Gilead Sciences (GILD) Stock Rating Reiterated After HIV Drug Approval
GILD's Trodelvy Receives EU Committee Backing for Breast Cancer
Gilead Sciences' (GILD) drug Trodelvy has received backing from the European Medicines Agency's (EMA) committee for its use in treating breast cancer. This endorsement is significant as it highlights the potential for Trodelvy to gain market authorization in the EU, which could enhance Gilead's portfolio in oncology. The move follows previous positive results from clinical trials demonstrating Trodelvy's effectiveness. Market analysts anticipate this approval may influence Gilead's stock performance positively as it opens new avenues for revenue generation.
Read More: GILD's Trodelvy Receives EU Committee Backing for Breast Cancer
Gilead Sciences (GILD) Quarterly Report Leads to Morgan Stanley Reassessment
Morgan Stanley has reassessed its outlook for Gilead Sciences (GILD) following the company's recent quarterly report. GILD reported revenue of $6.36 billion for the last quarter, reflecting a year-over-year decrease of 4%. The company's earnings per share (EPS) were reported at $1.58, slightly below analysts' expectations of $1.60. This reassessment by Morgan Stanley could influence investor sentiment and GILD's stock performance in the near term.
Read More: Gilead Sciences (GILD) Quarterly Report Leads to Morgan Stanley Reassessment
Gilead Sciences (GILD) DEF 14A Filing Details for April 21
Gilead Sciences Inc (GILD) filed its DEF 14A on April 21. This document provides details about the company's governance and executive compensation. The filing is essential for shareholders as it outlines voting procedures and important proposals for the annual meeting. Shareholders typically review such information to make informed decisions on company leadership and strategy.
Read More: Gilead Sciences (GILD) DEF 14A Filing Details for April 21
Gilead (GILD) acquires Tubulis for $5 billion investment
Gilead Sciences (GILD) has announced the acquisition of Tubulis, a company specializing in antibody-drug conjugates, for a sum of $5 billion. This acquisition reflects Gilead's strategic investment to enhance its pipeline in cancer therapies. The increasing focus on advanced treatment options in oncology could impact Gilead's market position and future earnings. The transaction is expected to strengthen Gilead's capabilities in developing targeted therapies.
Read More: Gilead (GILD) acquires Tubulis for $5 billion investmentMore Health Care stocks
Frequently asked questions
Is Gilead Sciences Inc. in the S&P 500?
Yes. Gilead Sciences Inc. (GILD) is a member of the S&P 500 index, classified in the Health Care sector.
What sector is GILD in?
Gilead Sciences Inc. is classified in the Health Care sector of the S&P 500 — pharmaceutical, biotech, device and managed-care companies.
Where can I find the latest GILD news?
This page collects recent Gilead Sciences Inc. (GILD) news and market analysis, each article summarized by AI and tagged with bullish, bearish, or neutral sentiment.
What is Gilead Sciences Inc.'s stock price?
As of the most recent market data, Gilead Sciences Inc. (GILD) traded at approximately $134.28. Prices move throughout the trading day, so this reflects the latest available quote rather than a live price.
What is Gilead Sciences Inc.'s market cap?
Gilead Sciences Inc. has a market capitalization of roughly $166.72B, based on its most recent share price and shares outstanding.
What is GILD's P/E ratio?
GILD trades at a trailing price-to-earnings ratio of about 18.5. The P/E ratio compares a company's share price to its earnings per share.